Myalgic encephalomyelitis
I am pleased that Dr Wilson (August 1990 JRSM, p 481) has paid me the compliment of giving my article on the vexed topic of 'myalgic encephalomyelitis' (April 1989 JRSM, p 215) serious attention and echoes our call! for a 'new approach' to the problem, based on an absence of prejudice and a sound clinical and social history. He also notes the parallels between neurasthenia and 'ME', although the former was not, as he writes, first described in 1884 2 • However, I only wish I could follow the rest of his arguments so clearly.
Dr Wilson states that I failed to realize that 'about 100%' of patients have an allergic diathesis and an allergic family history. I was indeed unaware of this remarkable finding. Unfortunately, I have been unable to trace the two sources cited for this observation, one an American paperback, the other a society newsletter. Similarly, I am afraid that neither I nor any of my colleagues have ever met anyone suffering from 'Alternate Multiple Personality'. Perhaps this was because I was again unaware of the relevant literature. However, in my defence I would not otherwise have known that the two references quoted, namely Dr Wilson's paper on allergic disease multiple personality and dowsing, and his paper on possession and multiple personality, are actually about chronic fatigue syndrome. Similarly, I would not have known that an article in the Christian Parapsychologist called 'Deliverance and dowsing' is on the psychopathology of allergy and ME, nor that information on treatment of ME would be published in a series of titles beginning with 'Current theological perspectives on possession'. It is becoming harder to keep up with the relevant literature.
Dr Wilson advocates treatment of ME based on exclusion of 'dietary, chemical or environmental challenges', and also by desensitization. However even if Dr Wilson is correct to state that all ME ĩ chronic allergy, and the recent studies in the peer reviewed literature erroneousv', such treatments have .not found support amongst specialists in allergy, and mdeed such 'unnecessary environmental and dietary restrictions' may lead to more serious disabilities than the diseases they purport to cure". S WESSELY Institute of Psychiatry, Camberwell, London SE5 8AF References 1 DavidA, Wessely S, PelosiA. Post-viralfatigue: time for a new approach. BMJ 1988;296:696-9 2 Wessely S. Old wine in new bottles: neurasthenia and 'ME'. Psychol Med 1990; 20:35-53 members in, say, Seattle may not be familiar with the clinical situation of patients in Miami. It is possible that this trend will cause problems in the future. Within the last half century, people have been victims of unethical experiments in at least one sophisticated western European country. Informed consent was invented afterwards and has evolved since that time. Informed consent may not be a complete and perfect protection, but surely its benefits outweigh its disadvantages? A WFox
Long-term central venous catheters
In this paper (October 1990 JRSM, p 620), Dennis et al. advocate the internal jugular vein as the preferred route for placement of silastic catheters.
They do not mention the use of the external jugular approach which has many advantages':
(1) The dissection is minimal.
(2) The procedure is therefore easy under local anaesthesia.
(3) Operating time is shorter. (4) There is less risk of major venous bleeding. (5) The line is easily removed. (6) The internal jugular is available for future use. The technique rarely fails although occasionally several attempts are necessary to persuade the catheter to lie in the superior vena cava and therefore an image-intensifier is recommended. 
Informed consent
Marsh should be congratulated for his perceptive editorial on informed consent (October 1990 JRSM, p 603). The introduction of bias into a randomized clinical trial (RCT), as a result of obtaining informed consent is clearly possible (see Dr Marsh's references), bUĩ s likely to be infrequent. Informed consent associated bias is likely to be dependent upon the stage of drug development, and the type of drug under investigation.
Early-phase RCTs have treatment groups with myriad differences between them due to variations between people and the expression of disease; the objective is to distil and examine one variation, that of a putative drug-effect. Bias due to the obtaining of informed consent would be expected to be balanced between treatment groups under these conditions.
In late-phase, large-scale trials the objective is usually to establish the safety and efficacy of the new drug under conditions more similar to its proposed ordinary clinical usage than the contrived early-phase studies. Informed consent associated bias should be added to the factors involved in comparing late-phase clinical trial populations and ordinary clinical populations, and might, quite properly, be part of a regulatory review. This issue might be most relevant in the study of psychotropic agents; for example, in the treatment of anxiety, it could be imagined that there could be a difference amongst patients with anxiety, between those who would and would not sign an informed consent document.
Secondly, there is controversy over how far to legislate the composition and activities of Ethics Committees (ECs) and Institutional Review Boards (IRBs). Often the best protectors of patients are those who know their special circumstances best. This may require considerable flexibility on the part ofIRBs and ECs, and flexibility is hard to prescribe in law. In practice, the more rigorous legislation in the United States almost never produces difficulty. However, there is a trend towards centralized IRBs, whose
